B. Dusak

Effects of modulation of basic fibroblast growth factor on tumor growth in vivo.

A. Yayon, D. Dexter, J. L. Gross, 1993, Journal of the National Cancer Institute.

Immune thrombocytopenic purpura and pregnancy.

M. Mennuti, A. Schreiber, B. Dusak, 1982, The New England journal of medicine.

Granulocyte-associated IgG in neutropenic disorders.

D. Guerry, A. Schreiber, B. Dusak, 1982, Blood.

Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization.

D. Dexter, E. Hamel, J. B. Jiang, 1990, Journal of medicinal chemistry.

Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization.

D. Dexter, E. Hamel, J. B. Jiang, 1990, Journal of medicinal chemistry.

Cytotoxicity of synthetic racemic ptilocaulin: A novel cyclic guanidine

B. Snider, P. Confalone, F. Hobbs, 1989, Investigational New Drugs.

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

J. Tolson, D. Kuritzkes, K. Squires, 2002, The Journal of infectious diseases.

Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

K. Paull, J. Plowman, D. Dexter, 1985, Cancer research.

Effects of plasma protein binding displacement on the pharmacokinetics, tissue and tumor concentrations and efficacy of brequinar, a highly protein-bound antitumor agent.

B. Aungst, B. Dusak, J. Blake, 1990, The Journal of pharmacology and experimental therapeutics.